Neoadjuvant strategies for pancreatic cancer

doi:10.3748/wjg.v20.i28.9374

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 28

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5175)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-5) series.

Item

Count

PDF

366

WORD

171

HTML

2220

Tables (1-5)

553

Sum=3310

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

958

Download

907

Sum=1865

Jul 28, 2014 (publication date) through Nov 12, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Jul 28, 2014; 20(28): 9374-9383
Published online Jul 28, 2014. doi: 10.3748/wjg.v20.i28.9374

Table 5 Studies on neoadjuvant chemotherapy for potentially resectable pancreatic cancer

Ref.	Study type	CT regimen	Patients (n)	Resection rate (%)	R0 resections rate (%)	OS median (mo)
Heinrich et al[66]	Prospective non-randomized phase II	Gemcitabine + cisplatin	28	93	80	26.5
Tajima et al[68]	Pilot study	S1 vs upfront surgery	34 (total) 13 (S1) vs 21 (upfront surgery)	100	84.6 vs 85.7	2 yr 55.6% vs 29.6%
Sho et al[69]	Single centre	GEM CRT (external beam 50 to 54 Gy)	61	97	92	NR
Van Buren et al[70]	Prospective phase II trial	FDR GEM + bevacizumab induction	59	72.8	38/43 (88.3%)	16. 8 (overall)
Van Buren et al[70]	Prospective phase II trial	GEM + bevacizumab Accelerated RT 30 Gy/10 fractions	59	72.8	38/43 (88.3%)	19.7 (resected patients)

CT: Chemotherapy; OS: Overall survival; NR: Not reported; GEM: Gemcitabine; CRT: Chemoradiotherapy.

Citation: Polistina F, Natale GD, Bonciarelli G, Ambrosino G, Frego M. Neoadjuvant strategies for pancreatic cancer. World J Gastroenterol 2014; 20(28): 9374-9383
URL: https://www.wjgnet.com/1007-9327/full/v20/i28/9374.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i28.9374